Plaque Psoriasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Plaque Psoriasis Market Outlook

Thelansis’s “Plaque Psoriasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Plaque Psoriasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Plaque Psoriasis Overview

Psoriasis, an immune-mediated inflammatory disease affecting skin and joints, is widely recognized as the most prevalent and often presents abnormalities in other bodily systems. The most common variant of psoriasis, known as plaque psoriasis (or psoriasis vulgaris), accounts for 80-90% of all cases. It is characterized by well-defined, erythematous, scaly plaques that frequently appear on specific areas like the elbows, knees, scalp, and the region between the buttocks. These plaques can vary in size, and patients may exhibit a localized condition with only a few lesions or a more generalized manifestation. Notably, the lesions are often symmetrically distributed, and about 80% of plaque psoriasis cases fall into the mild to moderate category, involving less than 10% of the body surface area. The etiology of psoriasis is multifactorial, with genetic predisposition being a significant factor. Additionally, various triggers, including trauma, infections, drugs, metabolic factors, stress, alcohol consumption, smoking, and sunlight exposure, can exacerbate the condition. Systemic drugs used to manage psoriasis encompass acitretin, methotrexate, cyclosporine, tacrolimus, hydroxyurea, 6-thioguanine, mycophenolate, fumaric acid esters, apremilast, and biologic agents. It's crucial to differentiate psoriasis from conditions like tinea corporis (dermatophyte fungal infection) and eczema, as they can occasionally coexist in the same patients. Psoriasis affects over 8 million individuals in the United States. Around 30 percent of those diagnosed with psoriasis also develop psoriatic arthritis. While psoriasis can manifest at any age, it typically exhibits two distinct onset peaks.

• The initial peak occurs between 20 and 30, and the second typically appears between 50 and 60.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: